key: cord-0710376-1ra3qwgy
authors: Lahooti, Behnaz; Poudel, Sagun; Mikelis, Constantinos M.; Mattheolabakis, George
title: MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential
date: 2021-12-09
journal: Front Oncol
DOI: 10.3389/fonc.2021.705634
sha: d3c89c36423dec0b096c2a0c4aa35e5d610ff8c3
doc_id: 710376
cord_uid: 1ra3qwgy

Angiogenesis is a key mechanism for tumor growth and metastasis and has been a therapeutic target for anti-cancer treatments. Intensive vascular growth is concomitant with the rapidly proliferating tumor cell population and tumor outgrowth. Current angiogenesis inhibitors targeting either one or a few pro-angiogenic factors or a range of downstream signaling molecules provide clinical benefit, but not without significant side effects. miRNAs are important post-transcriptional regulators of gene expression, and their dysregulation has been associated with tumor progression, metastasis, resistance, and the promotion of tumor-induced angiogenesis. In this mini-review, we provide a brief overview of the current anti-angiogenic approaches, their molecular targets, and side effects, as well as discuss existing literature on the role of miRNAs in angiogenesis. As we highlight specific miRNAs, based on their activity on endothelial or cancer cells, we discuss their potential for anti-angiogenic targeting in cancer as adjuvant therapy and the importance of angiogenesis being evaluated in such combinatorial approaches.

Angiogenesis is the physiological process for new blood vessel development from pre-existing ones. It is a highly coordinated, multistage process that occurs in physiological conditions, such as wound healing, the female reproductive cycle, and embryonic development, and many pathological conditions, including cancer. The angiogenic outcome highly depends on the balance of growth factors and angiogenesis inhibitors. Dysregulation of this balance leads to the increased or limited vascular network identified in a series of pathologies, such as retinopathies, inflammatory disorders, cardiovascular disorders, and tumors (1) (2) (3) .

The rapid growth of tumor cells requires the continuous supply of oxygen and nutrients, the diffusion of which in vivo is significantly limited at 100-500 microns from the nearest capillary. Solid tumors cannot grow more than 2-3 mm in diameter and thus become dormant without vascular support (4, 5) . The rapid proliferation of the tumor cells leads to their distant localization from the nearest capillary and the induction of hypoxia, a major driver of angiogenesis. Hypoxia leads to the secretion of many growth factors, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), cytokines, such as interleukin , and other pro-angiogenic mediators, such as sphingosine-1 phosphate (S1P), leading to the proliferation, migration and tumor-like formation of the nearby endothelial cells (5) (6) (7) (8) . The newly formed tumor vessels are markedly distinct from the normal capillaries due to their chaotic structure characterized by the absence of proper orientation, the limited pericyte and smooth muscle cell coverage, blunt capillary ends, increased leakiness, and limited perfusion. The increased leakiness provides fertile ground for tumor cell dissemination and metastasis, while the limited mural support often leads to their collapse due to the higher interstitial pressure of the tumoral area, increasing further the hypoxic conditions (3, 5, 9) .

Targeting the tumor vascular network with anti-angiogenic therapy, despite the excellent preclinical results and the high potential these provided, did not meet the expectations in the clinic, with ephemeral results and not significant benefit in overall survival in most tumors. A prominent reason for this is considered the induction of compensatory mechanisms due to increased hypoxia upon anti-angiogenic treatment, which drives the overexpression of other pro-angiogenic factors, blocks immune functionality, and limits the perfusion of cytotoxic therapies (10, 11) . During the last decade, the notion of vascular normalization as an outcome of anti-angiogenic therapy has risen, which can be achieved within a short therapeutic window during anti-angiogenic therapy. Tumor vascular normalization is expected to induce the integrity of the tumor vessels providing increased mural cell support, limited leakiness, inhibition of trans-endothelial cancer cell migration and metastatic incidence, and higher perfusion, which would limit the hypoxic areas and accommodate improved anti-cancer drug delivery in the tumoral area (12) (13) (14) . The majority of the studies have focused on VEGF inhibition, the main target of antiangiogenic therapies. A precise dosage of VEGF inhibitors has been demonstrated to inhibit vascular permeability by tightening cell-to-cell contacts and recruiting pericytes. VEGF is not the sole mediator of vascular permeability, as an increasing volume of data has highlighted the involvement of other molecular players and pathways, such as Angiopoietin-2, Semaphorin 3A, nitric oxide, superoxide dismutase-3, Notch, WNT, platelet-derived growth factor-B (PDGF-B) and bone morphogenetic protein (MBP) signaling in this process (10, 11, 13, 15, 16) .

Nucleic acid-based therapeutics have attracted attention for the treatment of several diseases, including cancer (17, 18) , inflammation (19) , or the development of vaccines, such as against SARS-CoV-2 (i.e. COVID-19) (20) (21) (22) . Among the different types of nucleic acids currently under research, miRNAs, natural molecules produced by the cells frequently transcribed along with protein-expressing genes (23, 24) , are commonly dysregulated in diseases, such as cancer, inflammation, and others. Not surprisingly, miRNAs were recognized as potential prognostic and diagnostic markers in cancer (23) (24) (25) (26) . More importantly, as miRNAs are small, non-coding RNAs that utilize the cell's RNA interference mechanism to regulate multiple gene expressions, miRNAs are evaluated as therapeutic tools against cancer (23) . An increasing body of literature focuses on dysregulated miRNAs for their properties as tumor suppressors or oncogenes, and on their action to either suppress or activate tumor-promoting pathways (23) . Exogenous delivery of miRNA constructs, similarly to the exogenous delivery of siRNAs, aims to replace or correct observed miRNA dysregulations. Unlike siRNAs though, miRNA replacement therapies induce the expression or increase the levels of nucleic acid sequences naturally occurring in the cells, which should have an indistinguishable effect on the endogenous miRNAs (23, 24) . Though this approach has limitations, the exogenous delivery of miRNAs should induce a strong beneficial effect on cells associated with the disease (i.e., cancer cells or cells of the tumor microenvironment with dysregulated miRNA expression) while having minimal effects on normal cells (i.e., absence of dysregulation) (27) .

Representatively, miR-34a is characterized as a master tumor suppressor against multiple cancer types, capable of regulating proliferation, migration (28) , apoptosis (29) , metastasis, senescence, differentiation, and immune responses (30) . Similarly, the clinical potential and translation of other miRNAs are currently undergoing. We are not outlining these studies, as several review publications focus on the current and past clinical trials [indicatively, refer to: (31) (32) (33) ]. As miRNAs are expressed in all types of cells, miRNAs regulate vascular development and angiogenesis in endothelial cells (EC). Landskroner-Eiger et al. (34) summarized the importance of miRNAs in angiogenesis from the perspective of the Dicer enzyme. Dicer enzyme is a key component in the biogenesis of miRNAs, and several studies evaluated the effect of Dicer deletion/inactivation in normal vascular development. Dicer activity affected angiogenesis, attributed to defective miRNA expression, dysregulating the expression of VEGF and its receptors. As miRNA dysregulation in cancer has been well documented (35) either through cell-to-cell communication between cancer cells and EC or EC intracellular miRNA dysregulation, utilization of miRNAs as targets or regiments can benefit cancer treatments through regulation of EC function and formation of blood vessels (36, 37) . There is an increasing interest in the combination of anti-angiogenic agents with traditional chemotherapeutics and several clinical trials pursued that approach (2, 38) . We sought to explore the use of miRNAs for cancer treatment due to their ability to regulate angiogenesis and focus on their potential and utilization as adjuvant therapies with chemotherapeutics because of their anti-angiogenic properties. Although there is a substantial body of literature focusing on miRNAs and angiogenesis, limited work exists on their combination with chemotherapeutics predominately due to their anti-angiogenic properties. Here, we present miRNAs that are frequently studied due to their angiogenesis-inhibiting capacity and have been combined with traditional chemotherapeutics, even when the utilization of these miRNAs was not because of their anti-angiogenic properties. blood vessel formation (41, 42) . The striking impact on angiogenesis, vascular morphology, and functions upon VEGF inhibition or deficiency, along with its overexpression in most solid tumors, including lung, breast, liver, and ovarian cancers, brought it to the frontline of anti-angiogenic targets, where it remains till today. The first FDA-approved anti-angiogenic drug was bevacizumab, a monoclonal antibody against VEGF (43, 44) . Bevacizumab, combined with chemotherapy, improved overall survival in colorectal cancer (45) and soon provided encouraging results when tested in ovarian, cervical, non-small cell lung cancers, and mesothelioma. Today, bevacizumab is FDAapproved for colorectal cancer, non-small cell lung cancer, renal cell carcinoma, cervical, fallopian tube cancer, peritoneal cancer, and glioblastoma, whereas it failed to provide clinical benefit in the majority of the other cancer types, including breast cancer, for which the FDA approval lasted for a short period (2) . Apart from bevacizumab, other antibody-based anti-angiogenic inhibitors are ramucirumab and aflibercept, which target VEGF receptor 2 (VEGFR2) or VEGF-A, VEGF-B and placental growth factor (PlGF), respectively. The rest of the angiogenesis inhibitors include small molecule or tyrosine kinase inhibitors that target one or more signaling pathways. Some of these tyrosine kinase inhibitors, such as sunitinib and regorafenib, inhibit a wide range of molecular targets and downstream mediators. The current, clinically administered anti-angiogenic inhibitors, their molecular targets, and the approved cancer types are presented below (2, 46-54):

• Bevacizumab, targeting VEGF-A, for glioblastoma, colorectal, cervical, fallopian tube, peritoneal, non-small cell lung cancers and renal cell carcinoma. • Ramucirumab, targeting VEGFR2, for gastric, gastroesophageal junction, non-small cell lung and colorectal cancers. 

As seen above, most anti-angiogenic drugs are targeting VEGF or VEGFR, either solely or in combination with other growth factor receptors or downstream kinases. Their administration provides encouraging clinical benefit; however, their application is not without side effects. The two most critical side effects of antiangiogenic therapy are the induction of tumor aggressiveness along with metastatic potential and the tumor angiogenesis relapse due to the development of resistance mechanisms. The induction of tumor aggressiveness and metastatic potential upon anti-angiogenic therapy is still under debate, as it has been reported in preclinical models, but not always verified in other studies, demonstrating the variability of this phenomenon (55) (56) (57) .

One of the limiting factors of anti-angiogenic therapy in cancer is that since cancer cells are not eradicated, as they do not consist the target of anti-angiogenic therapy, anti-angiogenic drugs have to be administered over long periods. The ephemeral outcome of anti-angiogenic therapy and the need for prolonged treatment eventually lead to the development of resistance upon anti-angiogenic inhibition. Resistance can be driven by the tumor cells, the stroma, immune cells, or endothelial progenitors, is mediated by the upregulation of alternative proangiogenic mediators, and presents cancer type-and patientspecific variability (8, 58) .

Systemic anti-angiogenic drug administration, both in the case of antibody-specific VEGF inhibition and a wide range of tyrosine kinase inhibitors, can lead to organ-or tissue-specific side effects (59) . A meta-analysis of five randomized clinical trials of metastatic colorectal, breast, and non-small cell lung cancers highlighted the risk of a thromboembolic event as another side effect of bevacizumab treatment in combination with chemotherapy (60). Cardiomyopathy and congestive heart failure have also been reported as side effects of antiangiogenic inhibitors (61) . Although the exact mechanism for cardiomyopathy and congestive heart failure upon VEGF signaling blockade has not yet been fully delineated, the current notion is that existing conditions depleting the vascular reserve, such as hypertension and coronary artery disease, may be considered risk factors for cardiotoxicity with VEGF signaling inhibitors, while reduced nitric oxide production, mitochondrial dysfunction and pericyte population depletion have been attributed as potential mechanisms (62, 63) . It has been further preclinically demonstrated that abrogation of the physiological VEGF activity can result in increased systemic (and coronary) vascular resistance and decreased cardiac output per se, which is the typical reason for cardiomyopathy development. Moreover, the roles of chemotherapy or radiation therapy as concomitant factors in VEGF blockade-induced cardiotoxicity have been further reported (63, 64) .

Two well-known side effects of anti-angiogenic therapy that go hand in hand are the increased rate of hemorrhage and the inhibited wound healing process, both of which are determining factors for the timing of surgical procedures (65) . Pulmonary hemorrhage with fatal outcome has been reported for non-small cell lung cancer patients with different anti-angiogenesis inhibitors, such as bevacizumab, ramucirumab, sunitinib, axitinib, and motesanib. A small percentage of gastrointestinal tumor patients developed bleeding at the tumor sites, while central nervous bleeding has also been reported (61, 65) . Impaired wound healing is a common issue. Angiogenesis is a pivotal part of the wound healing process, mediated by VEGF and other growth factors, thus is expected that VEGF inhibition hampers the inflammatory and granulation wound healing phases, pivotal for the wound healing process. As an alternative, milder antiangiogenic treatments have been proposed to overcome this issue (66) .To avoid wound healing deficiency of the surgical area anti-angiogenic treatment has to be terminated for at least four weeks before the surgical procedure so that the body will "wash out" the drug's effects (61, 65) .

The above demonstrate the impact and role of angiogenic factors in physiological vascular functions, the interdependence of the primary tumor and the tumor microenvironment, the need for highly targeted, vascular-specific anti-angiogenic approaches, and the consideration of anti-angiogenic therapies specifically targeting aberrant angiogenesis, without affecting regular angiogenic functions.

As research on miRNAs rapidly proliferates, miRNAs' contribution in tumor suppression via anti-angiogenic function presented multifaceted therapeutic potentials for these molecules. miRNAs have primarily been studied for their activity as single molecules against cancer (17, 35, 67) . With numerous miRNAs being able to regulate cell functions and pathways, the number of potential mechanisms of action of miRNAs in angiogenesis correlates to the potential pathways associated with angiogenesis. Nonetheless, similarly to traditional anti-angiogenic approaches, studies on miRNAs and angiogenesis have primarily focused in known, more traditional angiogenic pathways. Thus, miRNAs studies focus on angiogenic factor receptors or signaling molecules in ECs to inhibit tumor angiogenesis (68), among them more prominently being VEGF, VEGFR and PDGFR (69) (70) (71) . As numerous dysregulated miRNAs have been identified in tumor samples, here, we will present a few of the miRNAs with explicit action on angiogenesis and their identified molecular targets.

miR-34a, a master tumor suppressor, is one of the beststudied miRNAs, and, hence, its activity on tumor cells and cells of the tumor microenvironment has been thoroughly evaluated. Several studies have reported on miR-34a's ability to inhibit tumor angiogenesis. This activity takes place via multiple approaches, including the inhibition of the Silent Information Regulator 1 (Sirt1) expression, increase of the expression of acetylated Forkhead Box O1 (FoxO1) transcription factor, Notch1 targeting, and the p53 protein in endothelial progenitor cells and human cancer cells (72) (73) (74) (75) . miR-34a downregulation in EC induced BCL-2-overexpression and inhibition of apoptosis, while miR-34a upregulation suppresses tumor angiogenesis, EC proliferation, migration, and tube formation (76, 77) . miR-34a has also extensively been studied in combination with several chemotherapeutics, such as cisplatin (78, 79) , doxorubicin (80), sorafenib (81) , and paclitaxel (82), among others. Despite the well-studied anti-angiogenic properties of the miRNA, we did not find research on its combination with a chemotherapeutic agent based solely due to its anti-angiogenic properties, rather than miR-34a's activity on the tumor cells.

Similarly, the miR-29 family, miR-29a, miR-29b, and miR-29c, are downregulated in various cancers, such as endometrial carcinoma, hepatocellular carcinoma, gastric cancer, and breast cancer (83) (84) (85) (86) . miR-29b overexpression inhibits angiogenesis and tumorigenesis in vivo and weakens tube formation, cell proliferation, and migration in vitro (83) . miR-29b prevented tumor angiogenesis by targeting AKT3 and inhibited Akt3mediated VEGF and C-myc activations (86) . In a gastric cancer mouse model, miR-29a/c prevented tumor growth, tube formation, and suppressed angiogenesis by suppressing VEGF-A expression (87) . Similar to miR-34a, members of the miR-29 family have been attributed with tumor-suppressive properties and evaluated with several chemotherapeutic agents, such as cisplatin (88) , and paclitaxel (89), among others. Of interest, miR-29a has been reported to contribute to doxorubicin resistance in breast cancer cells (90) and inhibit doxorubicin resistance in colon cancer cells (91) . Li et al. (92) reported that cisplatin treatment induces upregulation of miR-29b, which suppressed invasion and angiogenesis of the cancer cells in vitro and inhibited tumor growth and neovascularization in vivo. The authors demonstrated that ectopic expression of miR-29b via intravenous administration in a subcutaneous xenograft mouse model of cervical cancer (HeLa cells) inhibited tumor growth and VEGF expression, corresponding to a decrease in vessel formation, although the authors did not evaluate this activity with the coadministration with cisplatin.

miR-221 and miR-222 modulated the angiogenic behavior of human umbilical vein endothelial cells (HUVECs) through the regulation of c-Kit expression (93) . As these miRNAs were among the most abundantly expressed miRNAs in ECs (94), Nicoli et al. reported that miR-221 is essential for angiogenesis, in the zebrafish model (95) . In human venous or lymphatic endothelial cells, miR-221 has been shown to inhibit angiogenesis (93, (96) (97) (98) . miR-221 has been identified as oncogenic in pancreatic cancer cells (99) , glioblastoma (100), breast cancer (101) , and lung cancer (102), among others. miR-221/222 have also been associated with increased chemoresistance to cisplatin in ovarian (103) and breast cancer cells (104) . Similar results have been reported with Adriamycin (doxorubicin) (105, 106), 5-fluorouracil (107) , and paclitaxel (108) . Representatively, in vivo analysis of downregulation of miR-221/222 through local injection in a breast cancer mouse model enhanced the cisplatin's tumor growth inhibition capacity, but no analysis on tumor vasculature took place (104) . In fact, in the in vivo studies of the miRNA-drug combinations, angiogenesis was not evaluated. This complex behavior is a representative example of the multi-faceted activity of miRNAs, which can be cancer-or cell-type-specific, and their combination with drugs can extend outside of the tumor cells, to the tumor microenvironment.

The expression of the most potent angiogenesis modulators in different tumors in terms of downstream targets of miRNAs has been extensively studied. Multiple miRNAs have been found to target VEGF since it is the most potent trigger for angiogenesis. miR-20 (109), miR-29b (110), miR-93 (111, 112) , miR-126 (113, 114) target the 3'-UTR region of VEGF-A mRNA. Following, we provide representative examples of miRNAs with antiangiogenic properties that also demonstrated anti-tumoral activity. miR-27b (115, 116) and miR-128 (69) suppress tumor progression and angiogenesis by targeting VEGF-C. miR-125b suppressed EC tube formation by inhibiting E-cadherin (117) . miR-192 targets EGR1 and HOXB9, leading to anti-tumor and anti-angiogenic activity in human ovarian epithelial tumors (118) . miR-200 family inhibited angiogenesis through direct and indirect mechanisms by targeting interleukin-8 (IL8) and CXCL1 secreted by the tumor endothelial and cancer cells (119) . Overexpression of miR-190 inhibited EMT and angiogenesis by inactivating AKT-ERK signaling (120) . miR-206 inhibited HGFinduced epithelial-mesenchymal transition (EMT) and angiogenesis in lung cancer, by suppressing Met/PI3k/Akt/ mTOR signaling (121) . miR-135a promoted cell apoptosis and inhibited cell proliferation, migration, invasion, and tumor angiogenesis by targeting the IGF-1 gene through the IGF-1/ PI3K/Akt signaling pathway in non-small cell lung cancer (NSCLC) (122) . Finally, miR-143 and miR-506, alone and in combination have been reported to affect angiogenesis, by inhibiting tube formation in HUVEC cells, while causing apoptosis to lung cancer cells (123) .

As the VEGF family and its downregulation have been implicated in drug resistance in tumor cells (124) (125) (126) , it is reasonable to predict that miRNAs with the capacity to target members of the VEGF family will become part of a cellsensitization goal for specific chemotherapeutics. Due to this reason alone, studies of miRNA-chemotherapeutic drugs combinatorial use for cancer treatment have the potential to proliferate in the future (Figure 1) . One representative example would be miR-126, where Zhu et al., (127) demonstrated that miR-126 decreased the minimum inhibitory concentration of Adriamycin and Vincristine by targeting VEGF-A. In Table 1 , we present a short list of studies with miRNAs with known antiangiogenic activity in combination with chemotherapeutics.

Illustratively, Wang et al. (155) studied the combination of miR-30a-5p with gefitinib to overcome drug resistance via regulation of the insulin-like growth factor receptor-1 (IGF1R) and hepatocyte growth factor receptor signaling pathways in NSCLC both in vitro and in vivo. Liang et al. (156) formulated exosomes to simultaneously deliver the anticancer drug 5-FU and a miR-21 inhibitor oligonucleotide (miR-21i) to 5-FUresistant colon cancer cells. This approach reversed drug resistance and significantly enhanced the drug's cytotoxicity in 5-FU-resistant colon cancer cells, compared to the single treatment with either miR-21i or 5-FU in an in vivo mouse model. Similarly. miR-375-3p, which has been reported to suppress tumorigenesis and reverse chemoresistance in colon cancer, along with 5-FU co-delivered in lipid-coated calcium carbonate nanoparticles were used to study the role of miR-375-3p in 5-FU-resistance in colorectal cancer (157, 158) .

It is evident that miRNAs can have a significant impact on angiogenesis and cancer treatment. As our knowledge on miRNA activity expands, the highly complex interaction between miRNA and angiogenesis due to autocrine or paracrine interactions will dictate the future potential of the miRNAs as therapeutic tools. One major hurdle of anti-cancer therapies, including the anti-angiogenic therapies described above, is the off-target effects due to non-specific tissue-or cell-targeting. This hurdle is further exacerbated with the miRNAs, as the tumor type and the multifaceted activity of the miRNAs can have synergistic or antagonistic therapeutic outcomes through the tumor microenvironment. Thus, the in vivo evaluation of the miRNAs needs to expand outside the tumor cell growth and incorporate aspects, such as angiogenesis. Another parameter to be taken into account for miRNA-based therapies is the promiscuous binding of high miRNA dose, causing multiple off-target effects. This significant hurdle of miRNA-based treatments can be resolved by miRNA cooperativity and lower miRNA doses, while it is noteworthy that the final outcome of the targets of the cooperating genes strongly depends on the cellular environment (159) . miRNA delivery has been challenging by itself, due to the nucleic acids' rapid elimination from the circulation, the abundance of nucleases in vivo, and the need for a carrier for the large hydrophilic nucleic acid constructs to enter the cells (23, 24) . The added complexity of the required cell type drug delivery specificity presents an additional challenge, which needs to be potentially overcome in the presence of an already impaired tumor vascular system (26) . Several novel delivery carriers have been developed and studied for the delivery of miRNAs. These include micelles, polymeric nanocarriers, lipid-based carriers, viruses, inorganic carriers, and systems with long-circulating properties and/or active targeting to receptors over-expressed in cancer cells (23) . Although the goal of a single organ and single-cell type targeting maybe be understandably impractical, these methodologies have provided significant benefits for minimizing off-target effects, increasing accumulation in the tumor, and preferentially increasing drug/nucleic acid concentration in specific cell types. Nonetheless, off-target effects will persist, even due to cell-to-cell communication.

This perspective has a significant impact when studying miRNA-drug combinations. Although in vitro analysis is fundamental to evaluate the synergistic/antagonistic behavior of a miRNA and a drug, the effect of the co-delivery of the miRNA-drug combination in vivo should take into consideration the anti-angiogenic properties of the miRNAs. Of course, this easily expands to other aspects of the tumor microenvironment, such as macrophages, though immunosuppressed animal models will present challenges for such evaluation. Though we recognize that there might be published research on miRNA-drug combination focusing on angiogenesis we overlooked, it is apparent from our analysis that currently the anti-angiogenic aspect of miRNAs co-delivered with drugs is not the primary focus, or is not studied in detail or at all, even for miRNAs with known anti-angiogenic properties. Simply stated, the question arises on how much of the enhanced anti-tumoral activity of miRNA-drug combinations can be attributed to the alteration of tumor cell behavior, angiogenesis, or both. Finally, another important aspect is the toxicity potential from the miRNAs. We described above the side effects attributed to the clinically used anti-angiogenic therapies, which have a clinical history with well-defined side effects. In contrast, miRNAs have not achieved clinical translation to the same extent, and, thus, similar or other side effects may not yet have become apparent. Nonetheless, the utilization of dysregulated miRNAs, their property of being natural cell products, and the development of novel nanocarriers provide significant advantages to overcome side-effects, commonly present in traditional antiangiogenic therapies (160) . In conclusion, miRNAs are fundamentally important targets and tools for cancer therapy. They have significant potential, based alone on their multifaceted activities on the tumor cells and tumor vascular microenvironment.

Identification of miRNAs with combined anti-angiogenic and antitumoral effects can provide significant advantages in cancer treatment, alone or in combination with clinically used chemotherapeutics.

BL, SP, CM, and GM contributed to the conception of the article, wrote and revised the final manuscript and agreed on its submission to this journal. All authors contributed to the article and approved the submitted version. 

Mechanisms of Angiogenesis in Microbe-Regulated Inflammatory and Neoplastic Conditions

Anti-Angiogenics: Current Situation and Future Perspectives

Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment

Tumor Angiogenesis: Therapeutic Implications

The Contribution of Angiogenesis to the Process of Metastasis

Anti-Angiogenesis for Cancer Revisited: Is There a Role for Combinations With Immunotherapy?

Endothelial RhoA GTPase Is Essential for In Vitro Endothelial Functions But Dispensable for Physiological In Vivo

Role of bFGF in Acquired Resistance Upon Anti-VEGF Therapy in Cancer

Defining the Role of the Tumor Vasculature in Antitumor Immunity and Immunotherapy

Principles and Mechanisms of Vessel Normalization for Cancer and Other Angiogenic Diseases

Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

Dual Inhibition of Ang-2 and VEGF Receptors Normalizes Tumor Vasculature and Prolongs Survival in Glioblastoma by Altering Macrophages

Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-Immunotherapy in Breast Cancer Lung Metastasis

Tumor Angiogenesis and Vascular Normalization: Alternative Therapeutic Targets

Extracellular Superoxide Dismutase, the Endothelial Basement Membrane, and the WNT Pathway: New Players in Vascular Normalization and Tumor Infiltration by T-Cells

The Role and Mechanisms of Action of microRNAs in Cancer Drug Resistance

Combination of Mir −143 and Mir−506 Reduces Lung and Pancreatic Cancer Cell Growth Through the Downregulation of Cyclin−Dependent Kinases

Anti-Inflammatory MicroRNAs and Their Potential for Inflammatory Diseases Treatment

COVID-19 Vaccines: The Status and Perspectives in Delivery Points of View

COVID-19 Vaccine Frontrunners and Their Nanotechnology Design

Advances in Gene-Based Vaccine Platforms to Address the COVID-19

Non-Viral Based miR Delivery and Recent Developments

miRNAs in Gastrointestinal Diseases: Can We Effectively Deliver RNA-Based Therapeutics Orally?

MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers

Nanoparticle Delivery and Tumor Vascular Normalization: The Chicken or The Egg? Front Oncol

The Promise of microRNA Replacement Therapy

MiR-34a Inhibits Proliferation and Migration of Breast Cancer Through Down-Regulation of Bcl-2 and SIRT1

Effect and Mechanism of miR-34a on Proliferation, Apoptosis and Invasion of Laryngeal Carcinoma Cells

MicroRNA-34 Family: A Potential Tumor Suppressor and Therapeutic Candidate in Cancer

How Close Are miRNAs From Clinical Practice? A Perspective on the Diagnostic and Therapeutic Market

The Potential for microRNA Therapeutics and Clinical Research

Therapeutic Advances of miRNAs: A Preclinical and Clinical Update

miRNAs as Modulators of Angiogenesis

The Role of MicroRNAs in Human Cancer

MicroRNAs: Opening a New Vein in Angiogenesis Research

Intracellular and Extracellular miRNAs in Regulation of Angiogenesis Signaling

Combination of Antiangiogenesis With Chemotherapy for More Effective Cancer Treatment

Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid

Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen

Abnormal Blood Vessel Development and Lethality in Embryos Lacking a Single VEGF Allele

Heterozygous Embryonic Lethality Induced by Targeted Inactivation of the VEGF Gene

Avastin), a Humanized Anti-VEGF Monoclonal Antibody for Cancer Therapy

Angiogenesis as a Therapeutic Target

Bevacizumab Plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Vandetanib (ZD6474): An Orally Available Receptor Tyrosine Kinase Inhibitor That Selectively Targets Pathways Critical for Tumor Growth and Angiogenesis

Lenalidomide-Based Maintenance Therapy Reduces TNF Receptor 2 on CD4 T Cells and Enhances Immune Effector Function in Acute Myeloid Leukemia Patients

The Novel Mechanism of Lenalidomide Activity

Renal Cell Carcinoma

New Knowledge of the Mechanisms of Sorafenib Resistance in Liver Cancer

Cabozantinib in Patients With Advanced and Progressing Hepatocellular Carcinoma

Available at

Anti-Tumoral Activity of Single and Combined Regorafenib Treatments in Preclinical Models of Liver and Gastrointestinal Cancers

Accelerated Metastasis After Short-Term Treatment With a Potent Inhibitor of Tumor Angiogenesis

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

Inherent Vice" in the Anti-Angiogenic Theory may Cause the Highly Metastatic Cancer to Spread More Aggressively

Tumor Angiogenesis: Causes, Consequences, Challenges and Opportunities

Pro-and Antiangiogenic Therapies: Current Status and Clinical Implications

Arterial Thromboembolic Events in Patients With Metastatic Carcinoma Treated With Chemotherapy and Bevacizumab

Adverse Effects of Anticancer Agents That Target the VEGF Pathway

Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition

Cardiotoxicity With Vascular Endothelial Growth Factor Inhibitor Therapy

R-CHOP With or Without Bevacizumab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma: Final MAIN Study Outcomes

Assessment of the Risk of Antiangiogenic Agents Before and After Surgery

Anti-Angiogenic Drugs: Involvement in Cutaneous Side Effects and Wound-Healing Complication

MicroRNA in Cancer: The Involvement of Aberrant MicroRNA Biogenesis Regulatory Pathways

New Insights Into the Regulatory Role of microRNA in Tumor Angiogenesis and Clinical Implications

microRNA-128 Plays a Critical Role in Human Non-Small Cell Lung Cancer Tumourigenesis, Angiogenesis and Lymphangiogenesis by Directly Targeting Vascular Endothelial Growth Factor-C

MicroRNA-26b-5p Inhibits Mouse Liver Fibrogenesis and Angiogenesis by Targeting PDGF Receptor-Beta

miR-181a/B-5p Regulates Human Umbilical Vein Endothelial Cell Angiogenesis by Targeting PDGFRA

miR-34a Repression of SIRT1 Regulates Apoptosis

MicroRNA-34a Induces Endothelial Progenitor Cell Senescence and Impedes Its Angiogenesis via Suppressing Silent Information Regulator 1

MicroRNA-34a Regulates the Longevity-Associated Protein SIRT1 in Coronary Artery Disease: Effect of Statins on SIRT1 and microRNA-34a Expression

MicroRNA-34a Attenuates VEGF-Mediated Retinal Angiogenesis via Targeting Notch1

MicroRNA-34a Functions as an Anti-Metastatic microRNA and Suppresses Angiogenesis in Bladder Cancer by Directly Targeting CD44

Downregulation of miR-34a Promotes Endothelial Cell Growth and Suppresses Apoptosis in Atherosclerosis by Regulating Bcl-2

Devere White RW. MiR-34a Chemosensitizes Bladder Cancer Cells to Cisplatin Treatment Regardless of P53-Rb Pathway Status

miR-34a Sensitizes Lung Cancer Cells to Cisplatin via P53/miR-34a/MYCN Axis

MiR-34a Overexpression Enhances the Inhibitory Effect of Doxorubicin on HepG2 Cells

Co-Targeting of DNA, RNA, and Protein Molecules Provides Optimal Outcomes for Treating Osteosarcoma and Pulmonary Metastasis in Spontaneous and Experimental Metastasis Mouse Models

Micellar Delivery of miR-34a

Modulator Rubone and Paclitaxel in Resistant Prostate Cancer

MicroRNA-29b Suppresses Tumor Angiogenesis, Invasion, and Metastasis by Regulating Matrix Metalloproteinase 2 Expression

The miR-29 Family: Genomics, Cell Biology, and Relevance to Renal and Cardiovascular Injury

MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA Through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma

MiRNA-29b Suppresses Tumor Growth Through Simultaneously Inhibiting Angiogenesis and Tumorigenesis by Targeting Akt3

Cell-Derived Microvesicles Mediate the Delivery of miR-29a/C to Suppress Angiogenesis in Gastric Carcinoma

MiR-29c Reduces the Cisplatin Resistance of Non-Small Cell Lung Cancer Cells by Negatively Regulating the PI3K/Akt Pathway

miR-29c Regulates Resistance to Paclitaxel in Nasopharyngeal Cancer by Targeting ITGB1

MicroRNA-29a Contributes to Drug-Resistance of Breast Cancer Cells to Adriamycin Through PTEN/AKT/GSK3beta Signaling Pathway

miRNA-29a Reverses P-Glycoprotein-Mediated Drug Resistance and Inhibits Proliferation via Up-Regulation of PTEN in Colon Cancer Cells

Chemotherapy-Mediated miR-29b Expression Inhibits the Invasion and Angiogenesis of Cervical Cancer

MicroRNAs Modulate the Angiogenic Properties of HUVECs

Target Recognition and Regulatory Functions

miR-221 Is Required for Endothelial Tip Cell Behaviors During Vascular Development

Regulation of the Expression and Activity of the Antiangiogenic Homeobox Gene GAX/ MEOX2 by ZEB2 and microRNA-221

The Manipulation of miRNA-Gene Regulatory Networks by KSHV Induces Endothelial Cell Motility

MiR-221-3p Targets Hif-1alpha to Inhibit Angiogenesis in Heart Failure

The Inhibition of the Highly Expressed miR-221 and miR-222 Impairs the Growth of Prostate Carcinoma Xenografts in Mice

Regulation of the P27(Kip1) Tumor Suppressor by

Promotes Cancer Cell Proliferation

MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1

MicroRNA Signatures of TRAIL Resistance in Human Non-Small Cell Lung Cancer

Promote Chemoresistance to Cisplatin in Ovarian Cancer Cells by Targeting PTEN/PI3K/AKT Signaling Pathway

Targeted Inhibition of miR-221/ 222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells

Downregulation of miR-221 Enhances the Sensitivity of Human Oral Squamous Cell Carcinoma Cells to Adriamycin Through Upregulation of TIMP3 Expression

Oral Squamous Cell Carcinoma Cells Are Resistant to Doxorubicin Through Upregulation of Mir221

miR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression

MiR-221-3p-Mediated Downregulation of MDM2 Reverses the Paclitaxel Resistance of Non-Small Cell Lung Cancer In Vitro and In Vivo

Regulation of HIF-1alpha and VEGF by miR-20b Tunes Tumor Cells to Adapt to the Alteration of Oxygen Concentration

GATA3 Suppresses Metastasis and Modulates the Tumour Microenvironment by Regulating microRNA-29b Expression

Identification of microRNA-93 as a Novel Regulator of Vascular Endothelial Growth Factor in Hyperglycemic Conditions

Role of microRNA-93 in Regulation of Angiogenesis

Beyond Conventional: The New Horizon of Anti-Angiogenic microRNAs in Non-Small Cell Lung Cancer Therapy

MicroRNA-126: A New and Promising Player in Lung Cancer

miRNA-27b Targets Vascular Endothelial Growth Factor C to Inhibit Tumor Progression and Angiogenesis in Colorectal Cancer

MicroRNA-27b, microRNA-101 and microRNA-128 Inhibit Angiogenesis by Down-Regulating Vascular Endothelial Growth Factor C Expression in Gastric Cancers

microRNA-125b Inhibits Tube Formation of Blood Vessels Through Translational Suppression of VE-Cadherin

A miR-192-EGR1-HOXB9 Regulatory Network Controls the Angiogenic Switch in Cancer

Tumour Angiogenesis Regulation by the miR-200 Family

Overexpression of microRNA-190 Inhibits Migration, Invasion, Epithelial-Mesenchymal Transition, and Angiogenesis Through Suppression of Protein Kinase B-Extracellular Signal-Regulated Kinase Signaling Pathway via Binding to Stanniocalicin 2 in Breast Cancer

Induced Epithelial-Mesenchymal Transition and Angiogenesis in Non-Small Cell Lung Cancer via C-Met /PI3k/Akt/mTOR Pathway

Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer

Multipronged Activity of Combinatorial miR-143 and miR-506 Inhibits Lung Cancer Cell Cycle Progression and Angiogenesis

Expression of Vascular Endothelial Growth Factor Receptors (VEGF-Rs) on Human Breast Cancer Cells Confers Chemoresistance

Autophagy Control by the VEGF-C/NRP-2 Axis in Cancer and Its Implication for Treatment Resistance

Vascular Endothelial Growth Factor C Promotes Breast Cancer Progression via a Novel Antioxidant Mechanism That Involves Regulation of Superoxide Dismutase 3

miR-126 Enhances the Sensitivity of Non-Small Cell Lung Cancer Cells to Anticancer Agents by Targeting Vascular Endothelial Growth Factor A

Combination Therapy With Bioengineered miR-34a Prodrug and Doxorubicin Synergistically Suppresses Osteosarcoma Growth

Synergistic Anti-Tumor Effect of Paclitaxel and miR-34a Combined With Ultrasound Microbubbles on Cervical Cancer In Vivo and In Vitro

Dual Drugs (microRNA-34a and Paclitaxel)-Loaded Functional Solid Lipid Nanoparticles for Synergistic Cancer Cell Suppression

Potential Using of microRNA-34A in Combination With Paclitaxel in Colorectal Cancer Cells

Cytosolic Co-Delivery of miRNA-34a and Docetaxel With Core-Shell Nanocarriers via Caveolae-Mediated Pathway for the Treatment of

miR-34a Increases the Sensitivity of Colorectal Cancer Cells to 5-Fluorouracil In Vitro and In Vivo

Co-Delivery of 5-Fluorouracil and miRNA-34a Mimics by Host-Guest Self-Assembly Nanocarriers for Efficacious Targeted Therapy in Colorectal Cancer Patient-Derived Tumor Xenografts

Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism Between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability

MiRNA-21 Silencing Mediated by Tumor-Targeted Nanoparticles Combined With Sunitinib: A New Multimodal Gene Therapy Approach for Glioblastoma

MicroRNA Modulation Combined With Sunitinib as a Novel Therapeutic Strategy for Pancreatic Cancer

Synthetic miR-145 Mimic Enhances the Cytotoxic Effect of the Antiangiogenic Drug Sunitinib in Glioblastoma

Development of microRNA-145 for Therapeutic Application in Breast Cancer

Efficacy of Gemcitabine Conjugated and miRNA-205 Complexed Micelles for Treatment of Advanced Pancreatic Cancer

miR-129 Promotes Apoptosis and Enhances Chemosensitivity to 5-Fluorouracil in Colorectal Cancer

miRNA-497 Enhances the Sensitivity of Colorectal Cancer Cells to Neoadjuvant Chemotherapeutic Drug

miR-27b and miR-34a Enhance Docetaxel Sensitivity of Prostate Cancer Cells Through Inhibiting Epithelialto-Mesenchymal Transition by Targeting ZEB1

Dihydroartemisinin/miR-29b Combination Therapy Increases the Pro-Apoptotic Effect of Dihydroartemisinin on

Expression

Theragnosis-Based Combined Cancer Therapy Using Doxorubicin-Conjugated microRNA-221 Molecular Beacon

miRNA-192-5p Impacts the Sensitivity of Breast Cancer Cells to Doxorubicin via Targeting Peptidylprolyl Isomerase A

Mir378a Enhances the Sensitivity of Liver Cancer to Sorafenib by Targeting VEGFR, PDGFRbeta and Craf

MiR-338-3p Inhibits Hepatocarcinoma Cells and Sensitizes These Cells to Sorafenib by Targeting Hypoxia-Induced Factor 1alpha

MicroRNA-193a and Taxol Combination: A New Strategy for Treatment of Colorectal Cancer

MicroRNA-143 Sensitizes Cervical Cancer Cells to Cisplatin: A Promising Anticancer Combination Therapy

Downregulation of miR-29 Contributes to Cisplatin Resistance of Ovarian Cancer Cells

Combinatory Treatment With miR-7-5p and Drug-Loaded Cubosomes Effectively Impairs Cancer Cells

MicroRNA-506-3p Increases the Response to PARP Inhibitors and Cisplatin by Targeting EZH2/beta-Catenin in Serous Ovarian Cancers

MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells

Combination Therapy of Gefitinib and miR-30a-5p may Overcome Acquired Drug Resistance Through Regulating the PI3K/AKT Pathway in Non-Small Cell Lung Cancer

Engineered Exosomes for Targeted Co-Delivery of miR-21 Inhibitor and Chemotherapeutics to Reverse Drug Resistance in Colon Cancer

miR-375-3p Suppresses Tumorigenesis and Partially Reverses Chemoresistance by Targeting YAP1 and SP1 in Colorectal Cancer Cells

MicroRNA-375-3p Enhances Chemosensitivity to 5-Fluorouracil by Targeting Thymidylate Synthase in Colorectal Cancer

Systems Biology-Based Investigation of Cooperating microRNAs as Monotherapy or Adjuvant Therapy in Cancer

MicroRNA Therapeutics: Principles, Expectations, and Challenges

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest